|Pronunciation||ba" ze dox' i feen|
|Trade names||Conbriza, Viviant, others|
|Other names||Bazedoxifene acetate, TSE-424; WAY-140424; WAY-TSE-424|
|Drug class||Selective estrogen receptor modulator (SERM)|
|Main uses||Osteoporosis after menopause|
|Side effects||Hot flushes, muscle spasms, swelling of the legs|
|Typical dose||20 mg OD|
|Chemical and physical data|
|Molar mass||470.613 g·mol−1|
|3D model (JSmol)|
Bazedoxifene, sold under the brand name Conbriza is a medication used to treat osteoporosis after menopause. It reduces the risk of spinal fractures but not hip fractures. It is taken by mouth.
Common side effects include hot flushes, muscle spasms, and swelling of the legs. Other side effects may include blood clots. It should not be used in pregnancy. It is a selective estrogen receptor modulator (SERM).
It is taken as 20 mg once per day.
|Effect: + = Estrogenic / agonistic. ± = Mixed or neutral. – = Antiestrogenic / antagonistic. Note: SERMs generally increase gonadotropin levels in hypogonadal and eugonadal men as well as premenopausal women (antiestrogenic) but decrease gonadotropin levels in postmenopausal women (estrogenic). Sources: See template.|
Bazedoxifene was developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. It is the result of a research collaboration between Wyeth Pharmaceuticals and Ligand Pharmaceuticals.
On October 3, 2013 the FDA approved the combination product of bazedoxifene 20 mg with 0.45 mg Premarin (conjugated estrogens) for the treatment of menopausal osteoporosis and the treatment of moderate to severe hot flushes. This is the first approved menopausal hormone therapy product that contains a SERM (bazedoxifene) and an estrogen.
Society and culture
- "Selective Estrogen Receptor Modulators". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 11 January 2022. Retrieved 8 January 2022.
- "Conbriza". Archived from the original on 6 January 2021. Retrieved 8 January 2022.
- "Bazedoxifene". drugs.com. Archived from the original on 2019-08-24. Retrieved 2021-03-11.
- Gordon W. Gribble (9 October 2010). Heterocyclic Scaffolds II:: Reactions and Applications of Indoles. Springer Science & Business Media. pp. 14–. ISBN 978-3-642-15732-5. Archived from the original on 12 April 2017. Retrieved 11 March 2021.
- "EPARs for authorised medicinal products for human use - Conbriza". European Medicines Agency. 26 May 2009. Archived from the original on 11 June 2009. Retrieved 2009-07-08.